Sanofi
venglustat
type 3 Gaucher disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews venglustat for type 3 Gaucher disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“The LEAP2MONO study is ongoing and results from its open-label phase will be presented in the future when available.”